DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20205220

A prospective randomised controlled study on the effects of myoinositol on ovarian functions and metabolic factors in women with polycystic ovarian syndrome

Pooja Singh, Suchismita Biswal, Santosh Kumar Verma

Abstract


Background: Polycystic ovary syndrome is one of the most common endocrine disorder affecting five to ten percent women of reproductive age group. Myoinositol has been reported to be helpful in PCOS women with deranged metabolic and ovarian factors. In this study, we have evaluated the effects of myoinositol in women with PCOS.

Methods: A total of 132 patients are included in the study. 66 patients in the study group were given myoinositol 4 gm daily for three months, while other 66 patients in the control group were given folic acid for the same duration. The parameters were evaluated at the beginning, six and twelve weeks after intervention.

Results: After completion of 12 weeks, myoinositol was found to have a significant effect on reduction of BMI of the patients. No changes was seen in the fasting insulin levels, but a significant decrease in fasting blood sugar levels of patients was seen. Also, a significant increase in serum HDL was seen in the study group. Luteal phase serum progesterone was also increased in the study group.

Conclusions: Myoinositol has got noticeable effects in reducing the BMI of PCOS women. We didn’t find any significant effect of the drug over the fasting insulin level. Serum HDL was increased in some patients. An increase in luteal phase progesterone was noticed which suggest that myoinositol may be beneficial in ovulation. However further studies are needed to establish the same.


Keywords


Myoinositol, Polycystic ovarian syndrome

Full Text:

PDF

References


Homburg R. Polycystic ovary syndrome- from gynaecological curiosity to multisystem endocrinopathy. Hum Reprod. 1996;11:29-39.

The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-7.

Nestler JE. Insulin resistance and the polycystic ovary syndrome: recent advances. Curr Opin Endocrinol Diabetes. 2000;7:345-9.

Genazzani AD, Lanzoni C, Ricchieri F, Baraldi E, Casarosa E, Jasonni VM. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecol Endocrinol. 2007;23:146-52.

Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril. 2004;81:114-9.

Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblast and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest. 1995;96:801-10.

Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22:141-6.

Nelson VL, Qin KN, Rosenfield RL. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001;86:5925-33.

Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, et al. Effects of D-chiroinositol in lean women with the polycystic ovary syndrome. Endocr Pract. 2002;8:417-23.

Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double-blind placebo-controlled trial. Eur Rev Med Pharmacol Sci. 2003;7:151-9.

Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol. 2008;24:139-44.

Kane MT, Norris M, Harrison RA. Uptake and incorporation of inositol by preimplantation mouse embryos. J Reprod Fertil. 1992;96:617-25.

Chiu TT, Rogers MS, Law EL, Briton-Jones CM, Cheung LP, Haines CJ. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod. 2002;17:1591-6.

Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, Marelli G, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. 2007;23:700-3.

Papaleo E, Unfer V, Baillargeon JP, Chiu TT. Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol. 2009;147:120-3.

Tabrizi R, Ostadmohammadi V, Lankarani KB, Peymani P, Akbari M, Kolahdooz F, Asemi Z. The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis. 2018;17:123.

Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, et al. Myoinositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. 2007;23:700-3.